Abstract: LBA3
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival (PFS) for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.
The Phase III randomized study, was led...
In the largest smoking cessation study of cancer patients to date, researchers from The University of Texas MD Anderson Cancer Center...
Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment...
The University of Texas MD Anderson Cancer Center has awarded Sheryl Harris, C.N.A., the Julie and Ben Rogers Award for Excellence in Patient Care. The annual award recognizes employees who consistently demonstrate excellence in their work and dedication to MD Anderson’s mission to end cancer. The award’s focus rotates annually among the areas of patient care, research, education, prevention and administration.
Peter WT Pisters...
The University of Texas MD Anderson Cancer Center goes gold for Kick Childhood Cancer Awareness Night at BBVA Stadium, Saturday, Sept. 21...
The University of Texas MD Anderson Cancer Center extends deepest sympathy to family and friends of philanthropist and energy...
Researchers at The University of Texas MD Anderson Cancer Center have confirmed a protein as an oncogene responsible for the most common and...